

NCTN Adolescent to Young Adult (AYA) Cancer Trials Portfolio (Open as of 10/15/2020)

Click on trial number to go to the associated ClinicalTrials.gov webpage, to view the protocol title and the study information.

Newly Diagnosed Disease

Soft Tissue Sarcoma

ARST1431

Germ Cell Tumors

AGCT1531

AGCT1532

Acute Lymphoblastic Leukemia (ALL)

A041501

Classical Hodgkin Lymphoma

S1826

TFE/Translocation Renal Cell Carcinoma (tRCC)

AREN1721

Recurrent Disease

Germ Cell Tumors

A031102 (TIGER)

Classical Hodgkin Lymphoma

E4412

Legend by Disease Types

Green = Soft Tissue Sarcoma

Yellow = Germ Cell Tumors

Blue = ALL

Lime green = Hodgkin Lymphoma

Purple = tRCC

Cross-disease trials

EAY131 (MATCH)

S1609 (DART)*

NCICOVID (NCCAPS)

*: COG not participating

NCTN Adolescent to Young Adult (AYA) Cancer Trials (Open as of 10/15/2020)

Protocol Number	Phase	Protocol Title
A031102	III	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A041501	III	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
AGCT1531	III	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532	III	A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors
AREN1721	II	A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
ARST1431	III	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temozolomide (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
E4412	I/II	A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
NCICOVID	Other	NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
S1826	III	A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
EAY131	II	Molecular Analysis for Therapy Choice (MATCH)
S1609*	II	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

*: COG not participating